Braverman ER - Search Results

1

Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D₂ agonist therapy: part 2.

Blum K, Chen TJ, Morse S, Giordano J, Chen AL, Thompson J, Allen C, Smolen A, Lubar J, Stice E, Downs BW, Waite RL, Madigan MA, Kerner M, Fornari F, Braverman ER. Blum K, et al. Among authors: braverman er. Postgrad Med. 2010 Nov;122(6):214-26. doi: 10.3810/pgm.2010.11.2237. Postgrad Med. 2010. PMID: 21084796 Clinical Trial.

2

Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour.

Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Comings DE. Blum K, et al. Among authors: braverman er. Pharmacogenetics. 1995 Jun;5(3):121-41. doi: 10.1097/00008571-199506000-00001. Pharmacogenetics. 1995. PMID: 7550364 Review.

3

The D2 dopamine receptor gene as a predictor of compulsive disease: Bayes' theorem.

Blum K, Wood RC, Braverman ER, Chen TJ, Sheridan PJ. Blum K, et al. Among authors: braverman er. Funct Neurol. 1995 Jan-Feb;10(1):37-44. Funct Neurol. 1995. PMID: 7649500 Review.

4

Prolonged P300 latency in a neuropsychiatric population with the D2 dopamine receptor A1 allele.

Blum K, Braverman ER, Dinardo MJ, Wood RC, Sheridan PJ. Blum K, et al. Among authors: braverman er. Pharmacogenetics. 1994 Dec;4(6):313-22. doi: 10.1097/00008571-199412000-00004. Pharmacogenetics. 1994. PMID: 7704037

5

Dopamine D2 receptor gene polymorphisms in Scandinavian chronic alcoholics: a reappraisal.

Blum K, Sheridan PJ, Wood R, Braverman ER. Blum K, et al. Among authors: braverman er. Eur Arch Psychiatry Clin Neurosci. 1995;245(1):50-2. doi: 10.1007/BF02191544. Eur Arch Psychiatry Clin Neurosci. 1995. PMID: 7786911 No abstract available.

6

The D2 dopamine receptor gene as a determinant of reward deficiency syndrome.

Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Cull JG, Comings DE. Blum K, et al. Among authors: braverman er. J R Soc Med. 1996 Jul;89(7):396-400. doi: 10.1177/014107689608900711. J R Soc Med. 1996. PMID: 8774539 Free PMC article. Review.

7

Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report.

Blum K, Braverman ER, Wood RC, Gill J, Li C, Chen TJ, Taub M, Montgomery AR, Sheridan PJ, Cull JG. Blum K, et al. Among authors: braverman er. Pharmacogenetics. 1996 Aug;6(4):297-305. doi: 10.1097/00008571-199608000-00003. Pharmacogenetics. 1996. PMID: 8873216

8

Substance use disorder exacerbates brain electrophysiological abnormalities in a psychiatrically-ill population.

Braverman ER, Blum K. Braverman ER, et al. Clin Electroencephalogr. 1996;27(4 Suppl):5-27. doi: 10.1177/1550059496027s0402. Clin Electroencephalogr. 1996. PMID: 8902324

9

Association of polymorphisms of dopamine D2 receptor (DRD2), and dopamine transporter (DAT1) genes with schizoid/avoidant behaviors (SAB).

Blum K, Braverman ER, Wu S, Cull JG, Chen TJ, Gill J, Wood R, Eisenberg A, Sherman M, Davis KR, Matthews D, Fischer L, Schnautz N, Walsh W, Pontius AA, Zedar M, Kaats G, Comings DE. Blum K, et al. Among authors: braverman er. Mol Psychiatry. 1997 May;2(3):239-46. doi: 10.1038/sj.mp.4000261. Mol Psychiatry. 1997. PMID: 9152988

10

Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors.

Blum K, Braverman ER, Holder JM, Lubar JF, Monastra VJ, Miller D, Lubar JO, Chen TJ, Comings DE. Blum K, et al. Among authors: braverman er. J Psychoactive Drugs. 2000 Nov;32 Suppl:i-iv, 1-112. doi: 10.1080/02791072.2000.10736099. J Psychoactive Drugs. 2000. PMID: 11280926 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

117 results

Search Page